Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating Cell-Free DNA Methylation Profiling Enables Detection, Distinction, and Estrogen Receptor Status Classification of Advanced Breast Cancer.

Cancer research·2026
Same author

Exploring the Utility of Cell-Free DNA Hydroxymethylation Profiling in Small-Cell Lung Cancer.

International journal of molecular sciences·2026
Same author

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Blood·2026
Same author

Radiation Dose-Dependent and -Independent Pulmonary Infiltrates in Patients with High-Grade Pneumonitis After Radiochemotherapy and Durvalumab Consolidation for Stage III NSCLC.

Diagnostics (Basel, Switzerland)·2026
Same author

Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report.

Cancer research communications·2026
Same author

Berzosertib enhances the sensitivity of pediatric diffuse midline glioma H3K27-altered cells to radiotherapy.

Cell death & disease·2026

Related Experiment Video

Updated: Jun 16, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

454

CRISPR Screen Identifies HDAC3 as a Novel Radiosensitizing Target in Small Cell Lung Cancer.

Ujas A Patel1, Mary Y Shi1, Jalal M Kazan1

  • 1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.

Molecular Cancer Therapeutics
|September 3, 2025
PubMed
Summary

Researchers identified HDAC3 as a novel target to enhance radiotherapy for small cell lung cancer (SCLC). Inhibiting HDAC3 increases DNA damage from radiation, improving treatment effectiveness in SCLC models.

More Related Videos

In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity
07:52

In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity

Published on: November 2, 2020

6.6K
HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries
10:10

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries

Published on: March 31, 2019

8.4K

Related Experiment Videos

Last Updated: Jun 16, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

454
In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity
07:52

In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity

Published on: November 2, 2020

6.6K
HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries
10:10

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries

Published on: March 31, 2019

8.4K

Area of Science:

  • Oncology
  • Cancer Biology
  • Radiotherapy Research

Background:

  • Small cell lung cancer (SCLC) is an aggressive malignancy with poor prognosis, especially in extensive-stage disease.
  • Current standard care for SCLC has limited efficacy, highlighting the need for novel therapeutic strategies.
  • Radiotherapy shows survival benefits in SCLC but can be improved with radiosensitizers.

Purpose of the Study:

  • To identify novel radiosensitizing targets in SCLC.
  • To investigate the efficacy and mechanism of targeting HDAC3 for radiosensitization in SCLC.

Main Methods:

  • Utilized a CRISPR knockout screen with an EpiDrug sgRNA library to identify radiosensitizing genes in SCLC cells treated with ionizing radiation (IR).
  • Validated HDAC3 as a target through genetic knockdown (KD) and pharmacologic inhibition (RGFP966).
  • Assessed radiosensitivity using cell viability and clonogenic assays, analyzed chromatin accessibility via ATAC-seq, and evaluated IR-induced DNA damage and repair pathways.

Main Results:

  • HDAC3 inhibition significantly enhanced radiosensitivity in SCLC cell lines, as evidenced by reduced cell viability and increased sensitivity in clonogenic assays.
  • HDAC3 deficiency led to increased chromatin accessibility, elevated IR-induced DNA double-strand breaks (DSBs), and impaired DSB repair, resulting in persistent DNA damage.
  • Combination therapy of HDAC3 inhibition with PARP inhibitors (Olaparib, Talazoparib) showed additive to synergistic effects; HDAC3 inhibition combined with IR significantly inhibited tumor growth in SCLC xenograft models.

Conclusions:

  • HDAC3 is a novel radiosensitizing target in SCLC.
  • Functional loss of HDAC3 enhances the generation and persistence of IR-induced DNA DSBs, sensitizing SCLC cells and tumors to radiotherapy.
  • Targeting HDAC3 represents a potential strategy to improve radiosensitization for SCLC treatment.